At baseline, before treatment started, SMA patients had significantly lower baseline myostatin levels compared to age‐matched controls, in line with previous reports of decreased myostatin expression in SMA patients [11, 20, 21]. The gene discussed is MSTN; the disease is proximal spinal muscular atrophy.